Source: BioPharma-Reporter

TCRS: Abzena to buy TCRS in latest boost to its ADC offering

Abzena is set to buy The Chemistry Research Solution (TCRS) in a deal one analyst says shows the firm's intentions to dominate the bio-conjugation space.

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
John Burt's photo - CEO of TCRS

CEO

John Burt

CEO Approval Rating

69/100

Read more